Najat Khan: Good morning, and thank you so much for joining us. I want to start by briefly framing where Recursion Pharmaceuticals, Inc. is today in its journey and evolution. Over the past decade, ...

Recursion Pharmaceuticals reported its fourth-quarter 2025 earnings, showcasing a significant beat on both earnings and revenue forecasts. The company reported an EPS of -$0.21, surpassing the ...

Management characterizes the current phase as an 'inflection point' where the focus shifts from building AI models to translating them into tangible clinical evidence and measurable impact.

The F-35 fighter jets operated by the U.S. Air Force and the Japan Air Self-Defense Force are equipped with software coded in C++. This C++ code is written in accordance with a coding standard called ...

Hello, everybody, and welcome to Recursion's Third Quarter 2025 (L)earnings Call. My name is Chris Gibson. I'm the Co-Founder and current CEO of Recursion, and I'm so delighted to have you all joining ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q2 2025 Earnings Call Transcript August 5, 2025 Recursion Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.41187 EPS, ...

Want smarter insights in your inbox? Sign up for our weekly newsletters to get only what matters to enterprise AI, data, and security leaders. Subscribe Now Writer, the full-stack generative AI ...

Hi, everybody. My name is Chris Gibson, Co-Founder and CEO of Recursion, delighted to be joining you on our L(earnings) today. And I'm joined by our Chief R&D and Commercial Officer, Najat Khan and ...